This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Effect of Z-338 in Subjects With Functional Dyspepsia

This study has been completed.
Information provided by:
Zeria Pharmaceutical Identifier:
First received: April 9, 2007
Last updated: November 21, 2010
Last verified: November 2010
Z-338; PhaseIIb, Single-centre, Randomized, Double-blind, Placebo-controlled, Parallel group study in Subjects with Functional Dyspepsia, evaluate the motility of gastro-duodenum by ultrasound

Condition Intervention Phase
Functioanl Dyspepsia Drug: Z-338 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: The Effect of Z-338 in Subjects With Functional Dyspepsia, Evaluate the Function of Gastro-duodenum by Ultrasound

Resource links provided by NLM:

Further study details as provided by Zeria Pharmaceutical:

Primary Outcome Measures:
  • Distal stomach square, Gastric emptying, Motility index, Duodenogastric reflux index

Estimated Enrollment: 40
Study Start Date: April 2007
Study Completion Date: July 2010
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   20 Years to 79 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Postprandial fullness, upper abdominal bloating and/or early satiety should be at least moderate for 2 days or more at the 7 days at Visit 1.
  • Upper abdominal pain, upper abdominal discomfort, postprandial fullness, upper abdominal bloating, early satiety, nausea, vomit and belching should be at least moderate for at least 2 symptoms for 2 days or more at the 7 days at Visit 1.

Exclusion Criteria:

  • Subjects that heartburn should be the most bothersome symptom
  • Subjects presenting with primary complaints relieved by stool movements (IBS)
  • Subjects with diabetes by treatment
  • Subjects that heartburn should be more than moderate
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00458328

Kawasaki Medical School
Kurashiki, Okayama, Japan, 701-0192
Sponsors and Collaborators
Zeria Pharmaceutical
Study Chair: Ken Haruma, MD, PhD Kawasaki Medical School
  More Information Identifier: NCT00458328     History of Changes
Other Study ID Numbers: 99010208
Study First Received: April 9, 2007
Last Updated: November 21, 2010

Additional relevant MeSH terms:
Signs and Symptoms, Digestive
Signs and Symptoms processed this record on September 21, 2017